Zevra Therapeutics Inc. Cash Flow Conversion Efficiency
Zevra Therapeutics Inc. cash flow conversion efficiency. Based on the latest financial reports, Zevra Therapeutics Inc. (ZVRA) has a cash flow conversion efficiency ratio of 0.035x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($4.71 Million) by net assets ($133.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Zevra Therapeutics Inc. (2012–2024)
Cash flow conversion efficiency of Zevra Therapeutics Inc. from 2012 to 2024. This chart illustrates how Zevra Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View ZVRA stock price for real-time trading data and today's change.
Zevra Therapeutics Inc. Cash Flow Conversion Ratio Explained
Zevra Therapeutics Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Zevra Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zevra Therapeutics Inc. ranked by their cash flow conversion efficiency. Also see Zevra Therapeutics Inc. stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Zoenn Design Co Ltd
SHE:300901
|
0.050x |
|
Farmacias Benavides S.A.B. de C.V.
MX:BEVIDESB
|
0.822x |
|
Suzhou Xingye Material Tech
SHG:603928
|
-0.006x |
|
Wam Global Ltd
AU:WGB
|
0.047x |
|
Veradigm Inc.
NASDAQ:MDRX
|
0.024x |
|
Puyang Refractories Group Co Ltd
SHE:002225
|
0.011x |
|
4D Molecular Therapeutics Inc
NASDAQ:FDMT
|
0.056x |
|
Marssenger Kitchenware Co. Ltd.
SHE:300894
|
-0.054x |
Annual Cash Flow Conversion Efficiency for Zevra Therapeutics Inc. (2012–2024)
The table below shows the annual cash flow conversion efficiency of Zevra Therapeutics Inc. from 2012 to 2024. Review ZVRA cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $39.67 Million | $-69.67 Million | -1.756x | -223.99% |
| 2023-12-31 | $61.86 Million | $-33.53 Million | -0.542x | -117.56% |
| 2022-12-31 | $75.12 Million | $-18.72 Million | -0.249x | -403.41% |
| 2021-12-31 | $127.12 Million | $10.44 Million | 0.082x | +181.27% |
| 2020-12-31 | $-66.41 Million | $-1.94 Million | 0.029x | -90.84% |
| 2019-12-31 | $-74.46 Million | $-23.74 Million | 0.319x | -60.85% |
| 2018-12-31 | $-66.57 Million | $-54.20 Million | 0.814x | +41.49% |
| 2017-12-31 | $-57.52 Million | $-33.10 Million | 0.575x | -63.86% |
| 2016-12-31 | $-18.70 Million | $-29.77 Million | 1.592x | -20.48% |
| 2015-12-31 | $-10.12 Million | $-20.27 Million | 2.003x | +231.64% |
| 2014-12-31 | $-24.30 Million | $-14.67 Million | 0.604x | +238.65% |
| 2013-12-31 | $-24.27 Million | $-4.33 Million | 0.178x | -97.48% |
| 2012-12-31 | $-627.22K | $-4.43 Million | 7.070x | -- |
About Zevra Therapeutics Inc.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under P… Read more